Earnings ·
CAMP4 Therapeutics reported a net loss of $33.5 million for Q2 2026, driven by a $20.9 million non-cash charge from…
CAMPCamp4 Therapeutics Corp
CAMP4 Therapeutics reported a net loss of $33.5 million for Q2 2026, driven by a $20.9 million non-cash charge from the fair value change of derivative tranche liabilities associated with its September 2025 private placement. The company secured regulatory clearance in Australia and Argentina to initiate a first-in-human Phase 1/2 clinical trial for CMP-002 targeting SYNGAP-1 related disorders, with launch expected in Q4 2026. Additionally, CAMP4 raised $50.1 million from the second closing of its private placement, extending its cash runway through the end of 2028. Cash and equivalents stood at $86.4 million as of June 30, 2026. The company operates in the biopharmaceutical industry, developing regulatory RNA-targeting therapeutics to treat genetic diseases.